{
    "clinical_study": {
        "@rank": "127957", 
        "arm_group": [
            {
                "arm_group_label": "Dl-3-n-butylphthalide", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days"
            }, 
            {
                "arm_group_label": "Cerebrolysin", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intravenous infusion of 100 ml saline intravenous q.d. for 10 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12\n      hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a\n      10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National\n      Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the\n      efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were\n      also analyzed among the three groups."
        }, 
        "brief_title": "Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke", 
        "completion_date": {
            "#text": "May 2010", 
            "@type": "Actual"
        }, 
        "condition": "Acute Cerebral Stroke Within 12 Hours for the First Time", 
        "condition_browse": {
            "mesh_term": [
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Acute ischemic stroke within 12 hours for the first time before entry into the study\n\n          -  National Institutes of Health Stroke Scale (NIHSS) score between 6 and 25\n\n        Exclusion Criteria:\n\n          -  with lacunar infarction\n\n          -  with cerebral hemorrhagic infarction\n\n          -  with epilepsy or epileptic persons\n\n          -  with history of neurological diseases\n\n          -  with myocardial infarction,\n\n          -  with renal and hepatic abnormalities\n\n          -  with metabolic diseases\n\n          -  with contraindications to antiplatelet treatments"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149875", 
            "org_study_id": "605872"
        }, 
        "intervention": {
            "arm_group_label": [
                "Dl-3-n-butylphthalide", 
                "Cerebrolysin", 
                "Placebo"
            ], 
            "intervention_name": "\"Dl-3-n-butylphthalide\",  \"Cerebrolysin\" and \"Placebo\" separately", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "3-n-butylphthalide", 
                "Cerebrolysin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acute ischemic stroke", 
            "Dl-3-n-butylphthalide", 
            "Cerebrolysin"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.", 
        "overall_official": {
            "affiliation": "Shanghai Jiao Tong University Affiliated Sixth People's Hospital", 
            "last_name": "Hao Chen, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Science and Technology Commission of Shanghai Municipality", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Scores range from 0 to 42, with higher scores indicating increasing severity", 
            "measure": "National Institutes of Health Stroke Scale (NIHSS) score", 
            "safety_issue": "No", 
            "time_frame": "At 11-day and 21-day after therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149875"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai 6th People's Hospital", 
            "investigator_full_name": "Hao Chen", 
            "investigator_title": "Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence", 
            "measure": "Barthel Index", 
            "safety_issue": "No", 
            "time_frame": "At 11-day and 21-day after therapy"
        }, 
        "source": "Shanghai 6th People's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai 6th People's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}